Neuropeptide Y: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
| Line 74: | Line 74: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
==External links== | ==External links== | ||
Revision as of 20:06, 4 September 2012
| Neuropeptide Y | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | |||||||||||
| Identifiers | |||||||||||
| Symbols | NPY ; PYY4 | ||||||||||
| External IDs | Template:OMIM5 Template:MGI HomoloGene: 697 | ||||||||||
| |||||||||||
| RNA expression pattern | |||||||||||
 | |||||||||||
| More reference expression data | |||||||||||
| Orthologs | |||||||||||
| Template:GNF Ortholog box | |||||||||||
| Species | Human | Mouse | |||||||||
| Entrez | n/a | n/a | |||||||||
| Ensembl | n/a | n/a | |||||||||
| UniProt | n/a | n/a | |||||||||
| RefSeq (mRNA) | n/a | n/a | |||||||||
| RefSeq (protein) | n/a | n/a | |||||||||
| Location (UCSC) | n/a | n/a | |||||||||
| PubMed search | n/a | n/a | |||||||||
|
WikiDoc Resources for Neuropeptide Y |
|
Articles |
|---|
|
Most recent articles on Neuropeptide Y Most cited articles on Neuropeptide Y |
|
Media |
|
Powerpoint slides on Neuropeptide Y |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Neuropeptide Y at Clinical Trials.gov Trial results on Neuropeptide Y Clinical Trials on Neuropeptide Y at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Neuropeptide Y NICE Guidance on Neuropeptide Y
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Neuropeptide Y Discussion groups on Neuropeptide Y Patient Handouts on Neuropeptide Y Directions to Hospitals Treating Neuropeptide Y Risk calculators and risk factors for Neuropeptide Y
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Neuropeptide Y |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Neuropeptide Y (NPY) is a 36 amino acid peptide neurotransmitter found in the brain and autonomic nervous system.
NPY has been associated with a number of physiologic processes in the brain, including the regulation of energy balance, memory and learning, and epilepsy.[1] The main effect is increased food intake and decreased physical activity.
NPY is secreted by the hypothalamus, and in addition to increasing food intake, it increases the proportion of energy stored as fat and blocks nociceptive signals to the brain[2].
NPY also augments the vasoconstrictor effects of noradrenergic neurons.
Role in regulation of feeding
NPY's role in regulating energy balance is well known. It forms part of the "lipostat" system along with leptin and corticotropin-releasing hormone (CRH). High NPY levels in the cerebrospinal fluid are associated with high food intake and decreased physical activity. Leptin, produced by adipocytes in response to high fat levels, is detected by the arcuate nucleus in the hypothalamus. Increased arcuate nucleus activity acts on the paraventricular nucleus to inhibit the production of NPY at that site, thus reducing feeding behaviour. Arcuate nucleus activity also stimulates the release of CRH which further decreases feeding and increases energy expenditure.
Correlation with stress and diet
Studies of mice and monkeys show that repeated stress— and a high-fat, high-sugar diet— stimulate the release of neuropeptide Y, causing fat to build up in the abdomen. Researchers believe that by manipulating levels of the appetite hormone, they could make fat melt from areas where it was not desired and accumulate at sites where it is needed.[3][4]
Higher levels of NPY may be associated with resilience against and recovery from posttraumatic stress disorder.[5]
Receptors
The receptor protein that NPY operates on is a G-protein coupled receptor in the rhodopsin like GPCR family. These receptors are metabotropic, causing metabolic changes in the target cell rather than directly opening ion channels. The protein contains seven membrane spanning domains and five subtypes have been identified in mammals, four of which are functional in humans.[6] Subtypes Y1 and Y5 have known roles in the stimulation of feeding while Y2 and Y4 seem to have roles in appetite inhibition (satiety). Some of these receptors are among the most highly conserved neuropeptide receptors.
See also
References
- ↑ Colmers WF, El Bahn B (2003). "Neuropeptide Y and Epilepsy". Epilepsy Currents/American Epilepsy Society. 2 (3): 53–8. PMID 15309085.
- ↑ users.rcn.com - Hormones of the Gut
- ↑ Thomas H. Maugh II (July 2, 2007). "Research points to way to eliminate belly fat". Chicago Tribune.
- ↑ Kuo, LE (2007). "Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome". Nature Medicine. 13 (7): 803–811. Unknown parameter
|coauthors=ignored (help); Unknown parameter|month=ignored (help) - ↑ Yehuda, Rachel (2006). "Plasma Neuropeptide Y Concentrations in Combat Exposed Veterans: Relationship to Trauma Exposure, Recovery from PTSD, and Coping". Biological Psychiatry. 59 (7): 660–663. ISSN 0006-3223. Retrieved 2007-08-23. Unknown parameter
|month=ignored (help); Unknown parameter|coauthors=ignored (help) - ↑ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacological Reviews. 50 (1): 143–50. PMID 9549761.
External links
- EMBL receptor database entry
- Neuropeptide+Y at the US National Library of Medicine Medical Subject Headings (MeSH)